Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
1 Answers
Mednet Member
Medical Oncology · The University of Texas Health Science Center at San Antonio
I have not experienced this situation yet in my own clinical practice but I would not offer adjuvant IO nor adjuvant radiation therapy for this patient.
- IO therapy has limited efficacy in this histology. This was shown best in the KEYNOTE-427 (monotherapy pembrolizumab in metastatic nccRCC, McDermo...